Login / Signup

Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.

Mitzi J WilliamsLilyana AmezcuaStanley L CohanJeffrey A CohenSilvia R DelgadoLe H HuaElisabeth B LucassenRebecca S PiccoloChloe R KoulourisJames M Stankiewicz
Published in: Neurology (2024)
This study provides Class II evidence that among patients aged 18-55 years with RMS, the improvement in NEDA-3 with ofatumumab was comparably better than with teriflunomide among patients self-identified as non-Hispanic Black, non-Hispanic Asian, non-Hispanic White, Hispanic/Latino, and other/unknown.
Keyphrases
  • african american
  • multiple sclerosis
  • mass spectrometry
  • ms ms
  • rheumatoid arthritis
  • systemic lupus erythematosus
  • open label